DBA Italia
.
  • Cerca prodotto





.
.
Login
.
.
.
Covid-19 IVD & RUO

KITS: ELISA, RAPID TESTS, RT-PCR, ASSAY

Wantai
Diagnostic Kit

ELISA

RAPID TEST

RT-PCR


Wazyme
Wazyme
Wazyme
Wazyme
Wazyme

Biotecon

Assay Genie

Assay Genie | New COVID19 QPCR Triplex Detection Kit

  • 1 Step RT-PCR kit
  • Simultaneous detects 2 X 2019-CoV2 genes & internal control (RNP) genes
  • Also includes positive control and RTase control
  • 100 reaction pack size
  • Research-Use-Only

ELISA Genie | Tocilizumab ELISA & ADA Kits

Recently, the FDA approved a Phase III clinical trial for the use of Tocilizumab (Actemra) in severe COVID19 patients. These are highly sought after kits at the moment.

New Tocilizumab ELISA and ADA kits

  • Detects free drug or ADA in serum/plasma
  • Human, NHP, Mouse, rat
  • Sensitivity 10ng/ml

Assay Genie | COVID19 Rapid Tests | Detect COVID19 in 15 minutes

The new COVID19 Rapid test is the latest in testing technology and allows for the detection of novel Coronavirus in 15 minutes with 10ul blood

Wazyme

Key Features

  • Detects IgG and IgM to 2019-nCoV in 15 minutes
  • 10ul blood or 20ul serum/plasma required
  • Room temperature storage
  • CE IVD certified

CloudClone

ELISA KITS Targets in Virus Infection

Also available ELISA Targets in Cytokine Storm. (Proteins and antibodies also available).


BPS Bioscience

Since there is no approved treatment for infection with the 2019-nCoV /SARS-CoV-2 virus, the causative agent of the COVID-19 pandemic these two kits have been designed to screen for inhibition of binding between the ACE2 protein found on the surface of target pneumocytes, and the Spike glycoprotein that extends from the viral envelope

ACE2:SARS-CoV-2 Spike Inhibitor Screening Assay Kit #79936

SARS-CoV-2 Spike:ACE2 Inhibitor Screening Assay Kit #79931

The kits have similar design, with either ACE2 or the Spike protein bound to an ELISA plate, followed by incubation with the test inhibitor. Labeled Spike or ACE2 protein is added, followed by detection with HRP-labeled antibody and a chemiluminescent substrate. The kits are available in either format, to provide flexibility in experimental design, and to help find selective inhibitors that bind to either the Spike or ACE2 proteins, respectfully.

Wazyme

ACE2 Inhibitor Screening Assay Kit, #79923

The expression levels of ACE2 may affect the severity of coronavirus infections, and ACE inhibitors have been shown to decrease the risk of pneumonia. The ACE2 Inhibitor Screening Kit can be used to screen for potent inhibitors of ACE2 activity

Wazyme

Note that BPS also offers Coronavirus Screening Services using these 3 kits.


Acro

There is no effective treatment for COVID-19 in the market. It is urgent to develop the 2019-nCoV inhibitors, for example vaccines, therapeutic antibodies and small molecular compounds against COVID-19. ACRO has developed the 2019-nCoV inhibitor screening kit based on the biotinylated ACE2 protein and 2019-nCoV S protein RBD. This inhibitor screening ELISA pair is designed to facilitate the identification and characterization of 2019-nCoV inhibitors.


Biovision

ANTIBODIES

Santacruz

biorbytltd

A snippet from our infectious disease product range


Prosci

In response to the Coronavirus COVID-19 pandemic, ProSci Inc has developed and manufactured COVID-19 (SARS-CoV-2, 2019-nCoV) antibodies and research reagents against the virus. Polyclonal antibodies and monoclonal antibodies are available for order against COVID-19 virus SARS-CoV-2 spike, envelope, and nucleocapsid protein. More polyclonal, monoclonal, and recombinant single domain antibodies are currently in our antibody production pipeline.

Find out products here

Prosci

For COVID-19(SARS-CoV-2) receptor reagents, check out our ACE2 products


CreativeBiolabs
CreativeBiolabs
  • Anti-SARS-CoV S Antibody CR3022 for ELISA MRO-1214LC
  • Anti-SARS-CoV S Antibody 80R for ELISA MRO-693LC
  • Anti-SARS-CoV S Antibody S109.8 for ELISA MRO-692LC
  • Anti-SARS-CoV S Antibody S230.15 for ELISA MRO-691LC
  • Anti-SARS-CoV S Antibody S227.14 for ELISA MRO-690LC
  • Anti-SARS-CoV S Antibody 508-573 for ELISA, WB MRO-689LC
  • Anti-SARS-CoV S Antibody 512-9 for ELISA, WB MRO-688LC
  • Anti-SARS-CoV S Antibody 73-121 for ELISA, WB MRO-677LC
  • Anti-SARS-CoV S Antibody S104.1 for ELISA MRO-614LC
  • Anti-SARS-CoV S Antibody 12-28-1 for ELISA, WB MRO-676LC
  • Anti-SARS-CoV S Antibody S103.3 for ELISA MRO-613LC
  • Anti-SARS-CoV S Antibody SC03-007 for ELISA MRO-700LC
  • Anti-SARS-CoV S Antibody S101.1 for ELISA MRO-611LC

More products available here


PROTEINS/INHIBITORS

MCE Medchem Express

SARS-CoV-2—Promising Antiviral Agents

Favipiravir (T-705) Selectively and potently inhibits the RNA-dependent RNA polymerase (RdRp) of RNA viruses. Shows good clinical efficacy in treating COVID-19.
Remdesivir (GS-5734) A nucleotide analog inhibitor of RdRp. Against SARS-CoV, MERS-CoV and Ebola virus. Effectively inhibits SARS-CoV-2 in vitro. Enters phase III trial.
Chloroquine Phosphate An antimalarial agent. Inhibits autophagy and toll-like receptors (TLRs). Effectively inhibits SARS-CoV-2 in vitro. FDA approved.
Hydroxychloroquine sulfate An antimalarial and anti-inflammatory agent. Inhibits TLR7/9 signaling. Efficiently inhibits SARS-CoV-2 infection in vitro. FDA approved.

MedChemExpress Anti-COVID-19 Compound Library based on Relevant Proteins :

We conduct Virtual Screening of approved compound library and clinical compound library based on 3CLpro (PDB ID: 6LU7), RdRp, Spike Glycoprotein (PDB ID: 6VSB), nsp15 (PDB ID: 6VWW), PLpro and ACE2 Structure.

Partial Screening Library Data:

SARS‑CoV‑2

Compounds

Information

Status

3CLpro

Saquinavir

An HIV Protease inhibitor.

FDA approved

Carfilzomib

An irreversible proteasome inhibitor.

FDA approved

Nelfinavir

An orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) and antiviral agent.

FDA approved

S Protein & ACE2

Bimosiamose

A nonoligosaccharide pan-selectin inhibitor and has anti-inflammatory effects.

Phase 2

RdRp

Zanamivir

An influenza viral neuraminidase inhibitor.

FDA approved

nsp15

Ribavirin

An antiviral agent against a broad spectrum of viruses including HCV, HIV,
and RSV.

FDA approved

PLpro

Epetraborole
hydrochloride

A leucyl-tRNA synthetase (LeuRS) inhibitor. Intended for the infections caused
by Gram-negative bacteria.

Phase 2


Creative Biomart
Creative Biomart

Cat#

Species

Description

Host

Spike‑19V

COVID‑19

Recombinant COVID‑19 Spike protein S1 subunit receptor binding domain (RBD), Mouse IgG1 Fc‑tagged

HEK293 cells

Spike‑191V

COVID‑19

Recombinant COVID‑19 Spike protein S1 subunit, His‑tagged

HEK293 cells

Spike‑192V

COVID‑19

Recombinant COVID‑19 Spike protein S1 subunit, Human IgG1 Fc‑tagged

HEK293 cells

Spike‑193V

COVID‑19

Recombinant COVID‑19 Spike protein S1 subunit, Mouse IgG1 Fc‑tagged

HEK293 cells

Spike‑194V

COVID‑19

Recombinant COVID‑19 Spike protein (S1+S2 ECD), His‑tagged

HEK293 cells

Spike‑195V

COVID‑19

Recombinant COVID‑19 Spike protein S1 subunit, His‑tagged

Baculovirus‑Insect Cells

N‑196V

COVID‑19

Recombinant COVID‑19 Nucleocapsid protein, His‑tagged

Baculovirus‑Insect Cells

Spike‑197V

COVID‑19

Recombinant COVID‑19 Spike protein (S2 ECD), His‑tagged

Baculovirus‑Insect Cells

Spike‑198V

COVID‑19

Recombinant COVID‑19 Spike RBD(receptor binding domain) protein, human IgG1 Fc‑tagged

HEK293 cells

N‑127V

COVID‑19

Recombinant COVID‑19 N protein, his‑tagged

E. coli

ACE2‑736H

Human

Recombinant Human ACE2, His‑tagged

HEK293 cells

ACE2‑68H

Human

Recombinant Human ACE2, human IgG1 Fc‑tagged

HEK293 cells

ACE2‑185H

Human

Recombinant Human ACE2, mouse IgG1 Fc-tagged

HEK293 cells

 nCoVS‑125V

COVID‑19

Recombinant COVID‑19(isolate Wuhan-Hu-1) S(ΔTM) protein

HEK293 cells

 nCoVNP‑126V

COVID‑19

Recombinant COVID‑19(isolate Wuhan-Hu-1) NP protein

HEK293 cells


ACRO BIOSYSTEMS

Trimer Structure S Protein Verified by SEC-MALS

An article published in Science determined a 3.5-angstrom-resolution cryo-electron microscopy structure of the 2019-nCoV S trimer in the prefusion conformation. To facilitate medical countermeasure development, ACROBiosystems has developed the full length S protein with a trimer structure. The molecular weight and polymer form of the protein was verified by SEC-MALS technology. Also offered high quality 2019-nCoV S1, S RBD, N, human ACE2 and other proteins. The bioactivity was verified by SPR and BLI.


Vector labs

Lectins from various sources have been shown to exhibit potent antiviral properties by inhibiting infection of clinically important viral pathogens. The antiviral activity of lectins is largely attributed to direct binding to viral envelope glycans and preventing entry of the virus into cells.

Vector Laboratories is an established manufacturer of many plant lectins that are described in the literature as valuable tools in ongoing research to elucidate their potential in suppression of viral activity. Below is a list of mannose-specific and mannose/glucose-specific lectins, available in unconjugated and conjugated formats.

Based on prior studies on coronaviruses such as SARS-CoV and MERS-CoV, mannose-specific plant lectins can be used to investigate antiviral properties of the novel coronavirus SARS-CoV-2, the virus that causes COVID-19.


BPS Bioscience

BPS also provides a number of recombinant proteins for coronavirus research:

  • ACE2 protein, #11003 ACE2 is the cellular receptor for several coronaviruses, including human respiratory coronavirus NL63, the SARS-coronavirus (SARS-CoV) and the novel coronavirus 2019-nCoV/SARS-CoV-2.
  • 2019-nCoV Spike, RBD #100687 and 2019-nCoV Spike S1 #100688 The Spike protein mediates viral entry into host cells by binding to ACE2 through the receptor-binding domain (RBD) in the S1 subunit and then fusing the viral and host membranes through the S2 subunit. BPS offers both the full S1 subunit or just the RBD region.
  • PLPro protein, #81091 PLPro is the Papain-Like Protease encoded by the SARS-coronavirus (SARS-CoV). It downregulates interferon production, leading to increased pathogenesis.
  • PLP2 protein, #81090 The NL63 coronavirus genome encodes two papain like proteases, PLP1 and PLP2. PLP2 downregulates the innate immune response to NL63 via disruption of the STING pathway
  • 14-3-3theta, #79038 14-3-3 theta has been observed to mediate nucleo-cytoplasmic shuttling of the N protein (coronavirus nucleocapsid protein) of the SARS-coronavirus (SARS-CoV).

Cat. #

Product

Size

11003-1

ACE2, His-tag

20 ug

11003-2

ACE2, His-tag

100 µg

100688-1

2019-nCoV Spike S1, Fc-tag

20 ug

100688-2

2019-nCoV Spike S1, Fc-tag

50 ug

100687-1

2019-nCoV Spike RBD, His-tag

50 ug

100687-2

2019-nCoV Spike RBD, His-tag

100 ug

81091

PLPro, His-tag

25 ug

81090

PLP2, His-tag

25 ug

79038

14-3-3 theta Protein, His-tag (Human)

20 ug


ProImmune

Pro5® MHC Class I Pentamers

ProT2® MHC Class II Tetramers

New products for understanding CD8+ and CD4+ T cell
responses to CoVID-19/SARS-CoV-2

ProImmune

The following product range of CoVID-19/SARS-CoV-2 specific  Pro5® Pentamers  and  ProT2® Tetramers  for a range of published CD8+ and CD4+ T cell epitopes is available ordering immediately.

CoVID-19/SARS-CoV-2-specific Pro5® Class I Pentamers

Allele

Peptide Code

Peptide Sequence

Epitope Origin

A*02:01

4320

LLLDRLNQL

N protein 223-231

A*02:01

4321

FIAGLIAIV

S protein precursor 1202-1210

A*02:01

4322

ALNTLVKQL

S protein precursor 940-948

A*02:01

4323

LITGRLQSL

S protein precursor 978-986

A*02:01

4324

NLNESLIDL

S protein precursor 1174-1182

A*02:01

4326

VLNDILSRL

S protein precursor 958-966

CoVID-19/SARS-CoV-2-specific ProT2® Class II Tetramers

Allele

Peptide Code

Peptide Sequence

Epitope Origin

DRB1*01:01

4329

GAALQIPFAMQMAYRF

S protein 873-888

DRB1*01:01

4330

MAYRFNGIGVTQNVLY

S protein 884-899

DRB1*01:01

4331A

QLIRAAEIRASANLAATK

S protein 993-1010

DRB1*04:01

4332

QALNTLVKQLSSNFGAI

S protein 939-955

DRB1*04:01

4331B

QLIRAAEIRASANLAATK

S protein 993-1010


BIOVISION INCORPORATED

MPBio
   
The right choice for antibodies, chemicals and molecular biology - via Umbria, 10 Segrate (MI) Tel. +39 0226922300
Fax +39 0226926058 +39 0226923535 info@dbaitalia.it -  P.IVA 07484470153 - Copyright (c) 2013. DBA Italia s.r.l. - Privacy Policy